Document is current

Article History

Accepted: 18 July 2021

First Online: 11 August 2021

Declarations

:

: This work was supported in part by a grant from the National Cancer Institute (I-Wen Pan, James C. Yao, and Ya-Chen Tina Shih; R01 CA225647).

: Daniel M. Halperin has received research funding from AAA, Lexicon, Incyte, Genentech, and Tarveda and has had consulting roles with AAA, Lexicon, Ipsen, and Curium. Ya-Chen Tina Shih has received consulting fees, travel, and accommodation for serving on a grants review panel for Pfizer Inc. and an advisory board for AstraZeneca. James C. Yao has had consulting roles with AAA, Chiasma, Crinetics, Ipsen, and Novartis. I-Wen Pan and Bumyang Kim have no conflicts of interest that are directly relevant to the content of this article.

: Not applicable.

: Not applicable.

: Pan conceptualized the study framework, designed tables and figures, analyzed and interpreted study findings, and drafted the manuscript. Halperin and Kim contributed critical reviews of the manuscripts identified from search criteria, commented on the interpretation of the study findings, and drafted the manuscript. Shih and Yao aided in determining the appropriateness of articles included in the review along with interpreting the results and revising the manuscript draft. All authors discussed the results and study conclusions. All authors reviewed and approved the manuscript.

: The authors thank the clinical librarian, Yimin Geng, of the Research Medical Library at The University of Texas MD Anderson Cancer Center for searching for and providing a list of the relevant literature for this review. We acknowledge Gary Deyter in the Department of Health Services Research for editing the manuscript.